Zvi, Ariealla, et al,
A very insightful and important post by Pillx.
If HU211 does, in fact, meet FDA fast track criteria, and if, as Pillx suggests, it allows rolling surrogate endpoints [with all the associated implications for a smaller/faster and less costly PH3], then fast track qualification for HU211 would also have significant implications for PARS ability to attract a strategic partner, since it lowers the time/cost/risk aspects.
P.S. Pillx's prior scientific/medical remarks have always been right on the money.........am merely looking for additional confirmation, as interpreting the FDA regs can be very convoluted. Assuming Pillx is correct extending the logic to the search for a strategic partner seems a natural........and perhaps a means for PARS to secure an even better negotiating position [royalty %, etc]
|
